![]() |
|
|
Vol. 280, Issue 3, 1228-1234, 1997
Department of Pharmacology and Toxicology, Center for AIDS
Research, The Comprehensive Cancer Center and Division of Clinical
Pharmacology, University of Alabama at Birmingham, Alabama
The effects of several anti-human immunodeficiency virus nucleoside
analogs were examined on neurite regeneration and mitochondrial DNA
(mtDNA) synthesis in nerve growth factor-primed PC-12 cells. Under
pharmacologically relevant concentrations, the exposure of cells to
2
,3
-dideoxyinosine (ddI), 2
,3
-dideoxycytidine (ddC) and
2
,3
-didehydro-3
-deoxythymidine (d4T) led to a marked dose-dependent
inhibition of neurite regeneration with a 50% inhibitory concentration
approximating 1, 5 and 15 µM, respectively. In contrast, 3
-azido-3
-deoxythymidine (AZT) and
-L-2
,3
-dideoxy-3
-thiacytidine (3TC) had no effect on
neurite regeneration. Inhibition of mtDNA synthesis by ddI was dose
dependent, and ddC at a concentration of 10 µM strongly reduced mtDNA
content by >75%. However, no inhibition of mtDNA synthesis was
detected in cells exposed to 10 µM 3TC or d4T and to 25 µM AZT,
suggesting a lack of definite correlation between mtDNA depletion and
blockage of neurite regeneration. High performance liquid
chromatographic analysis demonstrated that AZT, ddC, 3TC and d4T were
anabolized to their respective monophosphate, diphosphate and
triphosphate derivatives in the PC-12 cells. In addition, d4T was
phosphorylated to form its monophosphate, diphosphate and triphosphate
derivatives in isolated mitochondria, whereas ddC was metabolized only
to its monophosphate form and no phosphorylated metabolites of 3TC were
detected under the same conditions. In summary, the peripheral
neuropathy induced by ddC and ddI in patients with acquired immune
deficiency syndrome may be accounted for by the depletion of mtDNA
content in the neurons. As for d4T, some other mechanism(s) may be
involved in its clinical neurotoxicity. Both AZT and 3TC lacked any
substantial toxicity in our in vitro model, which is in
agreement with the clinical action of these drugs.
This article has been cited by other articles:
![]() |
A. Saitoh, T. Fenton, C. Alvero, C. V. Fletcher, and S. A. Spector Impact of Nucleoside Reverse Transcriptase Inhibitors on Mitochondria in Human Immunodeficiency Virus Type 1-Infected Children Receiving Highly Active Antiretroviral Therapy Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4236 - 4242. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Estes, K. H. Busse, and S. R. Penzak Pharmacogenetic Considerations in the Management of HIV Infection Journal of Pharmacy Practice, June 1, 2007; 20(3): 234 - 245. [Abstract] [PDF] |
||||
![]() |
A. S. Ray, B. I. Hernandez-Santiago, J. S. Mathew, E. Murakami, C. Bozeman, M.-Y. Xie, G. E. Dutschman, E. Gullen, Z. Yang, S. Hurwitz, et al. Mechanism of Anti-Human Immunodeficiency Virus Activity of {beta}-D-6-Cyclopropylamino-2',3'-Didehydro-2',3'-Dideoxyguanosine Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1994 - 2001. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Turchan, C.B. Pocernich, C. Gairola, A. Chauhan, G. Schifitto, D.A. Butterfield, S. Buch, O. Narayan, A. Sinai, J. Geiger, et al. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants Neurology, January 28, 2003; 60(2): 307 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Khoo, P. G. Hoggard, I. Williams, E. R. Meaden, P. Newton, E. G. Wilkins, A. Smith, J. F. Tjia, J. Lloyd, K. Jones, et al. Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3228 - 3235. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Birkus, M. J. M. Hitchcock, and T. Cihlar Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors Antimicrob. Agents Chemother., March 1, 2002; 46(3): 716 - 723. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J White Mitochondrial toxicity and HIV therapy Sex. Transm. Inf., June 1, 2001; 77(3): 158 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Bryant, E. G. Bridges, L. Placidi, A. Faraj, A.-G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J.-L. Imbach, B. Hernandez, et al. Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection Antimicrob. Agents Chemother., January 1, 2001; 45(1): 229 - 235. [Abstract] [Full Text] |
||||
![]() |
X.-R. Pan-Zhou, L. Cui, X.-J. Zhou, J.-P. Sommadossi, and V. M. Darley-Usmar Differential Effects of Antiretroviral Nucleoside Analogs on Mitochondrial Function in HepG2 Cells Antimicrob. Agents Chemother., March 1, 2000; 44(3): 496 - 503. [Abstract] [Full Text] |
||||